Indication: Lorlatinib (INN) is used to treat advanced or metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) mutations or ROS1 rearrangements, particularly in patients who have previously received ALK or ROS1 inhibitor therapy.

Pharmacology: Lorlatinib is a third-generation tyrosine kinase inhibitor (TKI) that targets ALK and ROS1 receptors, disrupting their activity. By blocking these receptors, lorlatinib disrupts signaling pathways crucial for cancer cell growth and survival, thus impeding tumor progression.

Dosage and Administration: The typical dosage of lorlatinib is 100 mg orally once daily, with or without food. Adjustments to the dosage may be required depending on individual patient factors and tolerability.

Interactions: Lorlatinib may interact with various medications, including potent CYP3A inhibitors and inducers. Patients should inform their healthcare providers about all medications taken to prevent potential interactions.

Side Effects: Common side effects of lorlatinib include fatigue, edema, cognitive issues (like memory impairment), weight gain, elevated cholesterol levels, and peripheral neuropathy. Serious adverse effects may comprise hepatotoxicity, interstitial lung disease/pneumonitis, and QT interval prolongation.

Precautions and Warnings: Patients on lorlatinib should be monitored for signs of hepatotoxicity, interstitial lung disease/pneumonitis, and QT interval prolongation. Regular liver function and pulmonary function tests are advisable, and patients should promptly report symptoms like shortness of breath or chest pain.

Overdose Effects: In instances of overdose, supportive measures are recommended. Specific effects of lorlatinib overdose are not well-documented, so management should focus on symptomatic and supportive care.